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Abstract We asked whether attempts to introduce head-
ache services in poor countries would be futile on grounds
of cost and unsustainability. Using data from a population-
based survey in the Republic of Georgia, an exemplary
poor country with limited health care, and against the
background of headache-attributed burden, we report on
willingness to pay (WTP) for effective headache treatment.
Consecutive households were visited in areas of Tbilisi
(urban) and Kakheti (rural), together representative of
Georgian habitation. Biologically unrelated adults were
interviewed by medical residents using a structured ICHD-
II-based diagnostic questionnaire, the MIDAS question-
naire and SF-36. The bidding-game method was employed
to assess WTP. Of 1,145 respondents, 50.0% had episodic
headache (migraine and/or tension-type headache) and
7.6% had headache on C15 days/month, which was not
further diagnosed. MIDAS scores were higher in people
with headache on C15 days/month (mean 11.2) than in
those with episodic headache (mean 7.0; P = 0.004).
People with headache had worse scores in all SF-36 sub-
scales than those without, but no differences were found
between headache types. Almost all (93%) respondents
with headache reported WTP averaging USD 8 per month
for effective headache treatment. WTP did not correlate
with headache type or frequency, or with MIDAS or SF-36
scores. Headache is common and headache-attributed
burden is high in Georgia, with a profound impact on
HRQoL. Even those less affected indicated WTP for
effective treatment, if it were available, that would on On behalf of Lifting The Burden: the Global Campaign against
Headache and the International Headache Society Russian Linguistic
Special Interest Group.
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Introduction
Primary headache disorders, in particular migraine and
tension-type headache (TTH), are common [1]. They cause
substantial disability amongst those affected and impose
secondary burdens on their families and work colleagues
[2]. Through lost productivity, they generate a very large
economic burden that falls upon society [3]. Throughout
the world, medical care for people with headache generally
fails to alleviate these burdens. In most developing coun-
tries, for example many in Eastern Europe including the
Republic of Georgia, primary headaches are altogether
neglected by health policy-makers, physicians and even by
some people affected by them, and treatment of headache
is not at all a part of medical care.
The ultimate objective of the Global Campaign against
Headache [4, 5] is to support the implementation of
effective headache services to meet locally assessed needs,
thereby reducing the burden of headache. This is chal-
lenging in a resource-limited world. Headache services are
manifestly not cost-free, and other priorities compete. In
wealthy economies, the high ﬁnancial cost of headache
disorders argues strongly for greater investment in head-
ache services since lost-productivity costs [3] are far higher
than service costs [6]. Is this also the case in poor countries,
or are attempts to introduce headache services in poor
countries merely an exercise in optimistic and well-
meaning futility on grounds of unsustainability?
The East European Republic of Georgia is an exemplary
(for our purposes) poor country. In the post-Soviet era,
social infrastructure is unsound, incomes for the majority
of people are low and health services, generally patchy, are
effectively non-existent for headache. A recent population-
based survey of the prevalence and burden of primary
headaches in Georgia [7] found levels of migraine (MIG)
and tension-type headache (TTH) in line with estimates
from other parts of the world [1]. What was unusual was a
very high prevalence (7.6%) of headache occurring on
C15 days/month, which was strongly associated with low
socio-economic status. Clearly, headache is very common
in Georgia and the needs of people affected by it are not
adequately met.
We had the opportunity, during this survey, to seek an
answer to the question we pose above. Using data from the
survey, we report on headache-attributed burden and
health-related quality of life (HRQoL) among people with
headache in Georgia as indices of need. In addition, and as
our principal purpose, we report on people’s willingness to
pay (WTP) for effective headache treatment, if it were
available in the country.
Methods
The Georgian National Council on Bioethics approved the
study protocol. All respondents were informed of the pur-
pose of the survey and gave their verbal consent prior to
participating.
The methods of the study, conducted during 2008, have
been reported in full previously [8]. Brieﬂy, four medical
residents, trained in understanding and applying the diag-
nostic criteria for primary headache disorders, visited 500
adjacent households in Tbilisi and 300 in Kakheti, the areas
selected being, respectively, representative of urban and
rural Georgian habitation. They interviewed all 1,701
adults living in these households, selecting, for the study,
husband and wife and any other biologically unrelated
adults (n = 1,145). A screening question asked whether
headache, ‘‘not related to ﬂu, hangover, cold or head
injury’’, had occurred at least once within the previous
year. When it had, further questions separated episodic
headache from headache occurring on C15 days/month. A
previously validated structured diagnostic questionnaire [8]
based on the International Classiﬁcation of Headache
Disorders, 2nd edition (ICHD-II) [9] was used to diagnose
MIG and/or TTH in cases of episodic headache. Cases of
headache occurring on C15 days/month were not further
diagnosed for this analysis but kept separate as a single
group.
Headache-attributed burden was assessed using the
Migraine Disability Assessment (MIDAS) questionnaire
[10], recording the numbers of lost days of school or paid
work, household work and family, social or leisure activ-
ities during the previous 3 months because of headache.
MIDAS score is derived as the sum of wholly lost days and
days of reduced productivity by[50%; any resulting over-
estimate is balanced by the under-estimate that arises from
ignoring days impaired by\50% [10].
HRQoL was assessed using the 36 Short Form (SF-36)
health survey questionnaire [11], a widely used generic
instrument developed by the Rand Corporation for the
Medical Outcomes Study, which has been tested, validated
and used in many chronic diseases including headache
[12]. SF-36 is a self-administered 36-item scale measuring
eight domains of health including physical functioning
(PF), role limitations due to physical problems (RP), bodily
pain (BP), general health (GH), vitality (VT), social
functioning (SF), role limitations due to emotional
68 J Headache Pain (2012) 13:67–74
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ceding 4 weeks. All items are scored 0 to 100, with a
higher score indicating better health. The eight domains are
aggregated into two higher order scores that measure the
physical component of HRQoL (Physical Component
Summary, or PCS) and the mental component (Mental
Component Summary, or MCS).
WTP was assessed by the bidding-game method [13].
Interviewers asked respondents with headache how much
money (in Georgian lari [GEL]) they would spend per
month for an effective medication package, which was
deﬁned as treatment achieving ‘‘very good’’ pain relief for
acute headache coupled with preventative medication
reducing headache frequency by more than one half. The
bidding began by ﬁrst asking whether the individual would
pay GEL 15 (USD 7.50) for the package. If the answer was
‘‘yes’’, the interviewer incremented the bid in steps of GEL
5 (USD 2.50) until the answer was ‘‘no’’, and the last sum
receiving a ‘‘yes’’ response was the WTP. If the initial
answer was ‘‘no’’, the interviewer reduced the bid by GEL
5 (USD 2.50) until the respondent said ‘‘yes’’, the ﬁrst sum
receiving this response then being the WTP.
Respondents’ wealth was assessed by interviewers as
low, intermediate or high based on impressions of the area
and quality of housing, possessions and apparent style of
living. For this analysis, those of low wealth (‘‘poorer’’)
were compared with those of intermediate and high wealth
combined (‘‘wealthier’’), as few were in the high-wealth
group.
Analysis
The outcome variables of the study were MIDAS scores,
scores for SF-36 sub-scales and PCS and MCS, and WTP
expressed in US dollars (USD). Comparisons were made
between episodic headache and headache occurring on
C15 days/month, and between MIG (including deﬁnite
[dMIG] and probable [pMIG]) and TTH (including deﬁnite
[dTTH] and probable [pTTH]). For SF-36, comparisons
were also possible between headache cases and those with
no headache.
Data were statistically analysed with the SPSS 13.0
software (SPSS Inc., Chicago, IL, USA) and the MedCalc
11.3.1.0 package (MedCalc Software, Mariakerke, Bel-
gium). Categorical data were expressed as absolute num-
bers (percent) and ordinal and metric variables as mean
[±standard deviation (SD)] and as median [interquartile
range (IQR)]. Comparisons between groups were calcu-
lated using the Chi-squared test for categorical data and the
Mann–Whitney U test or the Kruskal–Wallis test for
ordinal and metric variables as appropriate. If the Kruskal–
Wallis test was positive (P\0.05), then post hoc analysis
for pair-wise comparison of subgroups [14] was performed.
All probabilities were two-tailed, and P\0.05 was
regarded as statistically signiﬁcant; P values were not
adjusted for multiple comparisons and were considered
descriptive only.
Results
Prevalence data have been reported previously [7], and are
brieﬂy summarized here. Household response rates were
high: 92% (462 of 500) in Tbilisis and 100% (of 300) in
Kakheti. In the population-based sample of 1,145 respon-
dents [690 (60%) women, mean age 45.4±12.0 years], 659
(57.6%) had headache not related to ﬂu, hangover, cold or
head injury. Of these, 87 (7.6%) had headache on
C15 days/month. We treated these as a single separate
group. Of the 572 (50%) with episodic headache, 157
(13.7%) had MIG and 383 (33.4%) had TTH (these num-
bers each including 70 respondents who had both). Mainly
because of inconsistent responses, 102 (8.9%) cases were
unclassiﬁable. We excluded these from this analysis, and
report below on 557 respondents, 470 with episodic
headache and 87 with headache on C15 days/month.
MIDAS scores were available from 393 people [70.5%;
339 with episodic headache (69 MIG, 236 TTH, 34
MIG ? TTH) and 54 with headache on C15 days/month]
(Table 1). They were higher in those with headache on
C15 days/month [mean 11.19 (±11.02); median 10] than
in those with episodic headache [mean 6.95 (±7.32);
median 5; P = 0.004] and in those with MIG [mean 9.61
(±8.37); median 10] than in those with TTH [mean 6.03
(±6.85); median 5; P = 0.001]. MIDAS grades III and IV
(i.e, MIDAS score C11), indicating moderate or severe
impact, were more common in people with headache on
C15 days/month (38.9%) than in those with episodic
headache (17.7%; v
2 = 37.504; P\0.001) (Table 1).
SF-36 data were available from 1,066 respondents with
or without headache (93.1%) (Table 2). Figure 1 shows
SF-36 domain-speciﬁc quality-of-life scores among people
with no headache, episodic headache, and headache
occurring on C15 days/month. People without headache
had higher scores in all sub-scales than those with head-
ache, but no differences were found between respondents
with episodic headache and those with headache on
C15 days/month or between those with MIG and those
with TTH. No signiﬁcant correlations were observed
between headache frequency (interval-scaled) and any SF-
36 sub-scale (data not shown).
Data for WTP were available from 510 (91.6%) people
with headache, of whom 93% reported that they would pay
a mean of USD 8.1 (±8.7; median USD 5; IQR 5–5) per
month for effective treatment if it were available in the
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123country. People in Tbilisi (n = 274), the capital, would pay
more (mean USD 9.4 ± 9.6; median USD 5; IQR 5–10)
per month than those in rural Kakheti (n = 236; mean
USD 6.5 ± 7.3; median USD 5; IQR 5–5) and wealthier
people (n = 296) would pay more (mean USD 9.0 ± 9.3;
median USD 5; IQR 5–10) than poorer people (n = 214;
mean USD 6.8 ± 7.7; median USD 5; IQR 5–5). WTP did
not correlate with headache type or frequency, or with
MIDAS or SF-36 scores (data not shown).
Discussion
The data contributing to this analysis came from a popu-
lation-based survey of[1,000 respondents using sound and
validated epidemiological methods [7]. Response rates
were generally high: in the derivation of the original
sample, household response rate was 95% overall, allowing
little if any bias, whilst response rates within the sample for
SF-36 (93%) and WTP (92%) were also very good. Only
for MIDAS (70.5%) was the rate less satisfactory. It may
not be compatible with Georgian culture voluntarily to
admit that headache causes lost time, or it may be that
those who did not lose time saw the questions as pointless
(these possible explanations being counter-balancing in
whom they would exclude, again making signiﬁcant bias
unlikely). WTP data were collected contemporaneously
with other data allowing diagnosis and describing
headache-attributed burden. This made possible compari-
sons between diagnoses, and correlations between WTP
and burden.
We diagnosed episodic headache according to ICHD-II
[9] as far as was possible, although 102 cases (17.8% of
episodic headache cases) were unclassiﬁable (and excluded
from these analyses). Headache occurring on C15 days/
month might be any of a group of disorders, including
chronic MIG, chronic TTH and medication-overuse head-
ache (MOH), that are often but imprecisely referred to
collectively as ‘‘chronic daily headache’’; we preferred to
avoid this term. Headache on C15 days/month proved very
difﬁcult to diagnose by questionnaire, and might in some
cases require multiple diagnoses; therefore we analysed all
such cases together, as a separate group.
Headache-attributed burden is multidimensional, and
extends beyond the person immediately affected to family,
friends and work colleagues, and to society as a whole. It is
impossible to estimate it in its entirety. We have considered
aspects that appear of particular importance—HRQoL and
lost productive time. WTP is also an indicator of burden.
SF-36 demonstrated that HRQoL was reduced by
headache but this was not quantitatively dependent upon
headache type or frequency. The failure of SF-36 to dif-
ferentiate between episodic headache and headache on
C15 days/month is particularly surprising, but here is not
the place to speculate in detail on the cause. MIDAS, on the
other hand, revealed a greater burden from headache
Table 1 Headache-related disability assessed by MIDAS in people with episodic headache (MIG or TTH) or with headache occurring on
C15 days/month
All episodic headache
(n = 339)
MIG
(n = 69)
TTH
(n = 236)
MIG ? TTH
(n = 34)
Headache on C15
days/month (n = 54)
Days of missed work or school 1.14 (±1.46) 1.61 (±1.78) 1.03 (±1.37) 0.91 (±1.19) 1.91 (±3.28)
1 (0–2) 1 (0–2) 1 (0–2) 0 (0–2) 1 (0–2)
Days of work or school
with\50% productivity
1.54 (±1.76) 2.07 (±1.78) 1.31 (±1.56) 2.06 (±2.62) 2.50 (±2.52)
1 (0–2) 2 (1–3) 1 (0–2) 2 (0–2) 2 (0–3)
Days of no household work 1.35 (±1.50) 1.93 (±1.74) 1.19 (±1.40) 1.29 (±1.34) 2.06 (±2.36)
1 (0–2) 2 (1–3) 1 (0–2) 2 (0–2) 2 (0–3)
Days of household work
with\50% productivity
1.56 (±1.77) 2.07 (±1.78) 1.32 (±1.56) 2.24 (±2.63) 2.85 (±3.14)
1 (0–2) 2 (1–3) 1 (0–2) 2 (0–2) 2 (1–4)
Days of no social/family/leisure activity 1.35 (±1.50) 1.93 (±1.74) 1.17 (±1.38) 1.44 (±1.46) 1.87 (±2.10)
1 (0–2) 2 (1–3) 1 (0–2) 2 (0–2) 2 (0–3)
Total MIDAS score 6.95 (±7.32) 9.61 (±8.37) 6.03 (±6.85) 7.94 (±6.95) 11.19 (±11.02)
5 (0–10) 10 (5–15) 5 (0–10) 8 (0–10) 10 (4–15)
MIDAS grade I (%) 52.5 37.7 58.9 38.2 37.0
MIDAS grade II (%) 29.8 33.3 26.3 47.1 24.1
MIDAS grade III (%) 14.5 23.2 12.3 11.8 24.1
MIDAS grade IV (%) 3.2 5.8 2.5 2.9 14.8
Data are shown as mean (±SD) and median (IQR), or as prevalence (%)
IQR inter-quartile range, MIG migraine, TTH tension-type headache
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ache, which is expected.
HRQoL reﬂects people’s assessment of their general
well-being and position in life as perceived within the
context of their culture, value systems, goals and concerns
[15]. SF-36 is the most widely used HRQoL questionnaire
in patients with chronic diseases [11, 15] and has been
utilized in several epidemiological and clinic-based studies
on headache, all agreeing that people with MIG have lower
SF-36 scores than population controls [2, 17]; in one,
people with moderate to high disability from MIG had
lower HRQoL scores in all SF-36 domains [2] suggesting a
profound impact on HRQoL. Other studies have looked at
other headache types in addition to MIG [18–20], always
ﬁnding HRQoL to be negatively affected.
The MIDAS Questionnaire, on the other hand, reﬂects
disability. Originally designed as a screening instrument
for people severely affected by headache, who might most
beneﬁt from medical care, and to provide an outcome
measure for clinical practice [21–26], clinical trials [24,
27–31] and epidemiologic studies [10, 18, 32–39], it is a
measure of behavioural response to impairment rather than
of disability itself, producing scores expressing lost useful
time. Like HRQoL measures, it is intended to aggregate the
impact of illness on an individual over a period of time;
unlike SF-36, it is disease speciﬁc, although applicable to
headache rather than only to MIG [40]. It is essentially
sensitive to frequency, which may explain why, in our
study, MIDAS detected a relationship between headache
frequency and burden while SF36 did not. Being disease
speciﬁc, MIDAS cannot be applied to non-headache con-
trols, who, of course, lose no time from headache. In other
words, attribution to headache is explicit in the case of
MIDAS, but implicit and inferred from comparisons with
non-headache controls in the case of SF-36.
Together, these measures and the prevalence data reveal
a population burdened by headache, with unmet need for
health care. This is the context in which we explored WTP.
The results of the WTP enquiry are of interest for sev-
eral reasons. First, we found that [90% of people with
headache were willing to pay, out of their pockets from
their generally very limited resources, for effective head-
ache care. This is a striking argument against the view that
headache is a problem of wealthy countries and
Table 2 Health-related quality of life assessed by SF-36 in people with no headache, episodic headache or headache occurring on C15 days/
month
SF-36 domains No. headache (n = 418) Episodic headache (n = 561) Headache on C15 days/month (n = 87) P (Kruskal Wallis)
PF 65.8 (±15.8) 55.3 (±15.1) 54.3 (±20.5) \0.0001
2
70 (50–75) 55 (45–65) 45 (40–70)
RP 83.5 (±18.9) 69.7 (±18.4) 69.0 (±21.0) \0.0001
2
88 (75–100) 75 (50–88) 63 (50–88)
RE 99.2 (±4.4) 97.2 (±8.8) 98.9 (±2.8) \0.0001
2
100 (100–100) 100 (100–100) 100 (100–100)
BP 69.5 (±14.8) 59.6 (±13.3) 59.5 (±15.0) \0.0001
1
72 (56–84) 56 (52–68) 52 (52–72)
GH 65.2 (±14.5) 55.1 (±13.0) 55.5 (±14.4) \0.0001
1
65 (50–75) 50 (50–60) 50 (50–65)
VT 96.5 (±17.9) 81.9 (±36.0) 86.2 (±33.8) \0.0001
2
100 (100–100) 100 (100–100) 100 (100–100)
SF 88.9 (±19.5) 69.4 (±24.2) 63.6 (±25.0) \0.0001
1
100 (78–100) 65 (45–100) 45 (45–100)
MH 96.1 (±18.0) 81.2 (±36.0) 86.1 (±34.1) \0.0001
2
100 (100–100) 100 (84–100) 100 (100–100)
PCS 55.2 (±4.3) 51.1 (±5.5) 50.7 (±5.5) \0.0001
1
56 (54–58) 51 (48–56) 49 (48–57)
MCS 48.4 (±7.1) 42.6 (±7.8) 43.0 (±8.2) \0.0001
1
50 (44–54) 42 (40–48) 42 (39–50)
Post hoc analysis with pairwise comparison of sub-groups according to Conover [14]. Data are shown as mean (±SD) and median (IQR)
IQR inter-quartile range, MIG migraine, TTH tension-type headache
1 No headache differs from both episodic headache and headache occurring on C15 days/month, without signiﬁcant difference between the last
two
2 No headache differs from episodic headache, without signiﬁcant difference between episodic headache and headache occurring on C15 days/
month
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Second, while WTP varied with ﬁnancial means (results
not shown) as might be expected, it did so within a rela-
tively narrow range (75% of both wealthier and poorer
groups would pay between USD 5 and USD 10). This
suggests that WTP is driven strongly by need, and only
within limits by ability to pay, which is an important
ﬁnding. However, our method of assessing wealth was
inexact, because income in Georgian families is frequently
hidden, or provided by a family member who lives and
works outside the country and therefore not registered.
Direct questions about income are not welcome, and
responses would not necessarily reﬂect reality. Further-
more, in the rapid transition to a US-style market economy,
many people with university education lost their jobs and
became poor, while others, mostly young people, have
prospered better even without education. Therefore, normal
socioeconomic indicators do not work well, and so this was
an imprecise analysis. Third, WTP did not depend on
headache type or frequency. This demonstrates that people
with less-frequent headaches are similarly interested in
treating them to those with near-daily headache, and
strongly suggests that a headache service, if available in the
country, would be used not only by the minority of people
with headache on C15 days/month but rather by the entire
population of headache sufferers, seeking to reduce their
personal burden of headache and to have a better quality of
life. Fourth, of course all depends on alignment between
WTP and the actual cost of the service. Whilst a WTP of
USD 8 per month might seem rather low compared with
what is often spent in western countries, it would be suf-
ﬁcient for many people when set against the low general
costs in Georgia. Fifth, since not only the wealthy but also
people with low income were willing to pay at least
something, we believe these results are very important for
market analysis by the pharmaceutical industry, who
should have an interest in introducing modern anti-
migraine drugs (e.g., triptans) to the Georgian market. The
importance of this is in the following: without effective
drugs, headache services will remain limited, and, while
headache services are limited, the market for effective
drugs will remain depressed. This Catch-22 situation needs
urgently to be breached.
There is one caveat: we have recorded what people say
they would do in the (currently) abstract circumstances of
available good care; it is not certain, until empirically
tested, which we hope later to do, that they will actually do
it when the opportunity becomes real. Regardless of this,
and a sixth point of interest, WTP is an expression of
burden that probably captures more elements of it than
either HRQoL or disability measures.
We have something more to say about headache care in
Georgia. During the survey, we received the impression
that headache was not considered, by those affected, an
important medical problem. The majority of respondents
considered their headaches, whether MIG or TTH, to be a
natural part of their lives; people were surprised to learn
that headache could be treated effectively. Many were very
enthusiastic to hear that efforts were being made by Lifting
The Burden [4, 5] to establish a headache service in the
country. Funding of medical care in Georgia is a major
issue. In the Soviet era, the State guaranteed the necessary
minimum of wealth, and basic health-care services were
provided with no out-of-pocket payments. Transition from
this socialist system to a market economy has been
accompanied by a marked socioeconomic decline for many
inhabitants, and the development of signiﬁcant disparities.
Most people are not insured, and all costs for any treatment
are out-of-pocket expenses.
In these circumstances, would people, in a poor country,
pay for a service for primary headache disorders, which are
not life-threatening but ‘‘only’’ reduce quality of life? We
have found the answer to be ‘‘yes’’, with the caveat referred
to earlier. We assume that the answer would be the same in
other similarly poor countries, and believe that efforts to
introduce headache services in such countries are far from
futile, and must be continued.
Conﬂict of interest Dr. Lampl has received honoraria for planning
and conducting clinical trials, participating in advisory board meet-
ings and speaking from Allergan, AstraZeneca, Bayer, Biogen Idec,
Bristol-Myers Squibb, GlaxoSmithKline, Gru ¨nenthal, Jansen-Cilag,
Lilly, MSD, Menarini, Merck-Serono, Mundipharma, Pﬁzer, and
Sanoﬁ-Aventis, and ﬁnancial support for clinical research from: Al-
lergan, AstraZeneca, Bayer, Gruenenthal, Mundipharma, and Pﬁzer.
Professor Steiner has received speaker honoraria and/or travel
0 
20 
40 
60 
80 
100 
PF  RP  RE  BP  GH  VT  SF  MH  PCS  MCS 
S
F
-
3
6
 
s
c
o
r
e
s
 
(
m
e
d
i
a
n
)
 
 
 
Fig. 1 SF-36 domain-speciﬁc quality-of-life scores among people
with no headache open square, episodic headache gray ﬁlled square
or headache on C15 days/month black ﬁlled square. PF physical
functioning, RP role limitations due to physical problems, RE role
limitations due to emotional problems, BP bodily pain, GH general
health, VT vitality, SF social functioning, MH mental health, PCS
physical component summary, MCS mental component summary
72 J Headache Pain (2012) 13:67–74
123reimbursement from World Headache Alliance, European Headache
Federation, British Association for the Study of Headache, University
La Sapienza, Merck & Co Inc, GlaxoSmithKline, Bayer Healthcare
and Actavis; serves on the editorial advisory boards of Journal of
Headache and Pain and Research Ethics Review; serves or has served
as consultant to Datamonitor, Bayer Healthcare, MAP Pharmaceuti-
cals Inc, Merck & Co Inc and Mundipharma International Limited;
and has received research support from the World Headache Alliance,
the International Headache Society and the European Headache
Federation. Professor Jensen serves on the editorial boards of Journal
of Headache and Pain and Scandinavian Journal of Pain, is member
of the advisory board of Nordic Allergan and Medotech, has received
speaker honoraria and/or travel reimbursement from European
Headache Federation, Allergan, Pﬁzer, BerlinChemie and Merck.
Professor Stovner serves on scientiﬁc advisory boards for BTG
International Ltd. and Minster Pharmaceuticals plc; serves as an
Associate Editor of Journal of Headache and Pain and on the edi-
torial advisory board for Journal of the Norwegian Medical Associ-
ation; has received research support, speaker honoraria or travel
expenses from GlaxoSmithKline, Pﬁzer Inc, AstraZeneca, Allergan,
Inc., Nycomed, Desitin Pharmaceuticals GmbH and Merck Serono.
Dr. Katsarava serves on the editorial boards of Journal of Headache
and Pain and Headache, has received research support from the
German Federal Ministry for Research and Education and Bayer
Schering, and speaker honoraria and/or travel reimbursement from the
International Headache Society, European Headache Federation, Al-
lergan, Merck Serono, Bayer Shering, and has served as consultant to
Allergan. The other authors have no conﬂict of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution and reproduction in any medium, provided the original
author(s) and source are credited.
References
1. Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A
et al (2007) The global burden of headache: a documentation of
headache prevalence and disability worldwide. Cephalalgia
27:193–210
2. Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A,
Stewart WF (2003) Migraine headache disability and health-
related quality-of-life: a population-based case-control study
from England. Cephalalgia 23:441–450
3. Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J,
Lipton RB (2003) The prevalence and disability burden of adult
migraine in England and their relationships to age, gender and
ethnicity. Cephalalgia 23:519–527
4. Steiner TJ, World Headache Alliance (2004) Lifting the burden:
the global campaign against headache. Lancet Neurol 3:204–205
5. Steiner TJ, Birbeck GL, Jensen R, Katsarava Z, Martelletti P,
Stovner LJ (2010) Lifting the burden: the ﬁrst 7 years. J Head-
ache Pain 11:451–455
6. McCrone P, Seed PT, Dowson AJ, Clark LV, Goldstein LH,
Morgan M et al (2011) Service use and costs for people with
headache: a UK primary care study. J Headache Pain. doi:
10.1007/s10194-011-0362-0
7. Katsarava Z, Dzagnidze A, Kukava M, Mirvelashvili E, Djibuti
M, Janelidze M, on behalf of Lifting The Burden The Global
Campaign to Reduce the Burden of Headache Worldwide and the
Russian Linguistic Subcommittee of the International Headache
Society et al (2009) Primary headache disorders in the Republic
of Georgia: prevalence and risk factors. Neurology 24:1796–1803
8. Kukava M, Dzagnidze A, Janelidze M, Mirvelashvili E, Djibuti
M, Fritsche G et al (2007) Validation of a Georgian language
headache questionnaire in a population-based sample. J Headache
Pain 8:321–324
9. Headache Classiﬁcation Subcommittee of the International
Headache Society (2004) The international classiﬁcation of
headache disorders: 2nd edn. Cephalalgia 24(Suppl 1):9–160
10. Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Li-
berman JN (2000) Validity of the Migraine Disability Assessment
(MIDAS) score in comparison to a diary-based measure in a
population sample of migraine sufferers. Pain 88:41–52
11. Tarlov AR, Ware JE, Greenﬁelds S, Nelson EC, Perrin E, Zu-
bkoff M (1989) The Medical Outcomes Study: an application of
methods for monitoring the results of medical care. JAMA
262:925–93013
12. Stewart AL, Greeﬁeld S, Hays RD, Wells K, Rogers WH, Berry
SD et al (1989) Functional status and well-being patients with
chronic conditions. Results from the Medical Outcomes Study.
JAMA 262(suppl 7):907–913
13. Dong H, Kouyate B, Cairns J, Sauerborn R (2005) Inequality in
willingness-to-pay for community-based health insurance. Health
Policy 72:149–156
14. Conover WJ (1999) Practical nonparametric statistics, 3rd edn.
Wiley, New York
15. Lipton RB, Hamelsky SW, Stewert WF (2001) Epidemiology and
impact of Haeache. In: Silberstein SD, Lipton RB, Dalassio DJ
(eds) Wolff’s headache and other head pain. Raven Press, New
York, pp 85–107
16. Solomon GD (1997) Evolution of the measurement of quality of
life in migraine. Neurology 48(Suppl 3):10–15
17. Terwindt G, Launer L, Ferrari M (2000) The impact of migraine
on quality of life in the general population. The GEM study.
Neurology 55:624–629
18. Bussone G, Usai GS, Grazzi L, Rigamonti A, Solari A, D’Amico
D (2004) Disability and quality of life in different primary
headaches: results from Italian studies. Neurol Sci 25:105–107
19. Wang SJ, Fuh JL, Lu RS, Juang KD (2001) Quality of life differs
among headache diagnoses: analysis of SF-36 survey in 901
headache patients. Pain 89:285–292
20. Guitera V, Mun ˜oz P, Castillo J, Pascual J (2002) Quality of life in
chronic daily headache. A study in a general population. Neu-
rology 58:1062–1065
21. Hu XH, Golden W, Bolge SC, Katic B, Chen YT, Wagner S et al
(2010) Predictability of future attacks by migraineurs: a pro-
spective observational study. Headache 50:1296–1305
22. Dowson AJ, Kilminster SG, Salt R (2008) Clinical proﬁle of bot-
ulinum toxin A in patients with chronic headaches and cervical
dystonia: a prospective, open-label, longitudinal study conducted
in a naturalistic clinical practice setting. Drugs R D 9:147–158
23. Peres MF, Silberstein S, Moreira F, Corchs F, Vieira DS, Abra-
ham N et al (2007) Patients’ preference for migraine preventive
therapy. Headache 47:540–545
24. D’Amico D, Solari A, Usai S, Santoro P, Bernardoni P, Frediani
F et al (2006) Improvement in quality of life and activity limi-
tations in migraine patients after prophylaxis. A prospective
longitudinal multicentre study. Cephalalgia 26:691–696
25. Rothrock JF, Parada VA, Sims C, Key K, Walters NS, Zweiﬂer
RM (2006) The impact of intensive patient education on clinical
outcome in a clinic-based migraine population. Headache
46:726–731
26. Klapper J, Lucas C, Røsjø Ø, Charlesworth B (2004) ZODIAC
study group Beneﬁts of treating highly disabled migraine patients
with zolmitriptan while pain is mild. Cephalalgia 24:918–924
27. Silberstein SD, Marmura MJ, Shaw J, Yu S (2010) Headache
prophylaxis with BoNTA: patient characteristics. Headache
50:63–70
J Headache Pain (2012) 13:67–74 73
12328. Matchar DB, Harpole L, Samsa GP, Jurgelski A, Lipton RB,
Silberstein SD et al (2008) The headache management trial: a
randomized study of coordinated care. Headache 48:1294–1310
29. Freitag F, Smith T, Mathew N, Rupnow M, Greenberg S, Mao L
et al (2008) Effect of early intervention with almotriptan vs
placebo on migraine-associated functional disability: results from
the AEGIS Trial. Headache 48:341–354
30. Garcı ´a ML, Baos V, La ´inez M, Pascual J, Lo ´pez-Gil A (2008)
Responsiveness of migraine-ACT and MIDAS questionnaires for
assessing migraine therapy. Headache 48:1349–1355
31. Dowson A, Bundy M, Salt R, Kilminster S (2007) Patient pref-
erence for triptan formulations: a prospective study with zolmi-
triptan. Headache 47:1144–1151
32. Lucas C, Ge ´raud G, Valade D, Chautard MH, Lante ´ri-Minet M
(2006) Recognition, therapeutic management of migraine in
2004, in France: results of FRAMIG 3, a French nationwide
population-based survey. Headache 46:715–725
33. Gedikoglu U, Ucler S, Inan LE, Coskun O, Tunc T (2006) A
preliminary study: validity and reliability of Turkish translation
of migraine disability assessment (MIDAS) questionnaire in
Turkish patients with chronic tension type headache. Int J Neu-
rosci 116:1337–1345
34. Soon YY, Siow HC, Tan CY (2005) Assessment of migraineurs
referred to a specialist headache clinic in Singapore: diagnosis,
treatment strategies, outcomes, knowledge of migraine treatments
and satisfaction. Cephalalgia 25:1122–1132
35. Hung PH, Fuh JL, Wang SJ (2006) Validity, reliability and
application of the Taiwan version of the Migraine Disability
Assessment Questionnaire. J Formos Med Assoc 105:563–568
36. Henry P, Auray JP, Gaudin AF, Dartigues JF, Duru G, Lante ´ri-
Minet M et al (2002) Prevalence and clinical characteristics of
migraine in France. Neurology 59:232–237
37. Lante ´ri-Minet M, Radat F, Chautard MH, Lucas C (2005) Anx-
iety and depression associated with migraine: inﬂuence on
migraine subjects’ disability and quality of life, and acute
migraine management. Pain 118:319–326
38. Pradalier A, Auray JP, El Hasnaoui A, Alzahouri K, Dartigues JF,
Duru G et al (2004) Economic impact of migraine and other
episodic headaches in France: data from the GRIM2000 study.
Pharmacoeconomics 22:985–999
39. Lipton RB, Stewart WF, Sawyer J, Edmeads JG (2001) Clinical
utility of an instrument assessing migraine disability: the
Migraine Disability Assessment (MIDAS) questionnaire. Head-
ache 41:854–861
40. Stewart WF, Lipton RB, Whyte J, Dowson A, Kolodner K, Li-
berman JN et al (1999) An international study to assess reliability
of the Migraine Disability Assessment (MIDAS) score. Neurol-
ogy 53:988–994
74 J Headache Pain (2012) 13:67–74
123